Table 2.
Comparison of National Institutes of Health Stroke Scale scores of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) and placebo groups at baseline and on days 7, 14, and 90 after treatment
| CEGI group | Placebo group | t-value | P-value | ||
|---|---|---|---|---|---|
| FAS analysis | Before treatment | 8.08±2.66 | 7.68±2.12 | 1.35 | 0.177 |
| After treatment | |||||
| Days 7 | 5.96±2.4 | 6.42±4.99 | –0.79 | 0.433 | |
| Days 14 | 3.69±2.2 | 4.88±5.19 | 1.95 | 0.054 | |
| Days 90 | 2.54±1.9 | 3.53±2.65 | –2.99 | 0.004** | |
| PPS analysis | Before treatment | 8.14±2.67 | 7.74±2.16 | 1.28 | 0.203 |
| After treatment | |||||
| Days 7 | 5.99±2.41 | 5.96±2.35 | 0.08 | 0.933 | |
| Days 14 | 3.71±2.2 | 4.32±2.37 | –2 | 0.046* | |
| Days 90 | 2.51±1.85 | 3.53±2.66 | –3.04 | 0.003** |
Data are expressed as the mean ± SD, and analyzed using the rank-sum test and t-test. *P < 0.05, **P < 0.01. The full analysis set (FAS) consisted of 229 and 78 cases in in the CEGI and placebo groups, respectively. The per-protocol set (PPS) consisted of 218 and 73 cases in the CEGI and placebo groups, respectively.